Wave Life Sciences Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $65.4M-39.6% YoYTTM through 30 Jun 2026
Net Income -$202.5MTTM through 30 Jun 2026
Free Cash Flow -$193.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -332.4% |
| Operating Margin | -81.8% |
| Net Margin | -309.7% |
Returns
-44.6%ROE
-36.3%ROA
Balance Sheet Health
Debt / Equity0.03x
Current Ratio11.27x
Net Debt-$528.9Mnet cash position
Cash & Equivalents$368M
Quality Metrics
Altman Z-Score1.15
Piotroski F-Score1 / 9
FCF Margin-295.5%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $42.7M
Diluted EPS-$1.08TTMFY2025: $-1.21
Dividend
No dividend
Capital Allocation
Capex Intensity2.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration | $38.3M | +316.7% | View detailsWave expects to continue receiving milestone payments and research funding under its GSK collaboration. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.